αααααβααΎαHLUN-A β’ CPH
add
H Lundbeck A/S Class A
30.40Β kr
16 α§αααΆ, 5:19:59 PM ααααβααα +2 · DKK · CPH · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
αα·αααΈαα»α
29.05Β kr
α
αααααααααααα
29.05Β kr - 30.70Β kr
α
ααααααα½αααααΆαα
α»αααααα
23.30Β kr - 41.70Β kr
ααΎαβαα»αβααΈααααΆα
34.54Β αααΈααΆα DKK
ααα ααα½αααΌαααααα
119.00Β ααΆαα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
CPH
ααααααΆαααΈααααΆα
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(DKK) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 6.24Β αααΈααΆα | 17.91% |
α
αααΆαααααα·ααααα·ααΆα | 3.45Β αααΈααΆα | 15.06% |
α
αααΌααα»ααα | 1.15Β αααΈααΆα | 14.51% |
ααααΆααα
αααααα»ααα | 18.48 | -2.84% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | 1.53 | 10.87% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 2.14Β αααΈααΆα | 22.79% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 22.00% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(DKK) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 2.70Β αααΈααΆα | -47.25% |
ααααααααα»α | 54.22Β αααΈααΆα | 43.24% |
ααΆαααα½ααα»αααααΌαααα»α | 29.65Β αααΈααΆα | 92.31% |
ααΌαβααααα»α | 24.57Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 991.90Β ααΆα | β |
ααααααααααΉαααααα
| 1.17 | β |
ααα
ααααααΎαααααα | 7.64% | β |
ααα
ααααααΎααΎααα»α | 10.42% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(DKK) | ααΈααΆ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | 1.15Β αααΈααΆα | 14.51% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 632.00Β ααΆα | -34.24% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -111.00Β ααΆα | -18.09% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -2.48Β αααΈααΆα | -226.32% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | -1.97Β αααΈααΆα | -2,009.71% |
ααα αΌαααΆα
αααααΆααααααα | -544.88Β ααΆα | -180.75% |
α’αααΈ
H. Lundbeck A/S, commonly referred to as Lundbeck, is a Danish international pharmaceutical company engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The companyβs products are targeted at brain diseases, including depression, schizophrenia, Alzheimer's disease, Parkinson's disease and migraine.
Headquartered in Copenhagen, Denmark, Lundbeck has approximately 5,600 employees in more than 50 countries, and their products are registered in more than 100 countries. They have production facilities in Denmark, France and Italy and their research centers are based in Denmark and the US.
Lundbeck is listed on the Copenhagen Stock Exchange.
Lundbeck is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations Wikipedia
ααΆααααααΎαα‘αΎα
14 ααΈα αΆ 1915
αααααβαααααΆα
αα»ααααα·α
5,700